Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]
, 2018 Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M +2 more
core +1 more source
JAMA: The Journal of the American Medical Association, 1979 To the Editor.— Buselmeier et al (240:1270, 1978) have described a psoriatic patient who responded to dialytic therapy. They concluded that "the apparent success of dialysis in treatment of intractable psoriasis... may indicate application of this mode of therapy to psoriatic patients who do not have renal failure." Since the publication of their ...
Sima Halevy +3 more
openaire +7 more sources
Arthritis Care &Research, EarlyView.Objective Targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy.
Vienna Cheng +7 more
wiley +1 more source
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study [PDF]
, 2018 Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Armesto +40 more
core +1 more source
Arthritis Care &Research, EarlyView.Objective Metabolic syndrome (MetS) is a known comorbidity of psoriatic arthritis (PsA) and is associated with PsA disease activity. We aimed to explore the association between MetS and radiographic features (peripheral and axial) in PsA. Methods We included patients with PsA followed at our prospective observational cohort for the period between 1978 ...
Fadi Kharouf +6 more
wiley +1 more source
2D Visualization of the Psoriasis Transcriptome Fails to Support the Existence of Dual-Secreting IL-17A/IL-22 Th17 T Cells. [PDF]
, 2019 The present paradigm of psoriasis pathogenesis revolves around the IL-23/IL-17A axis. Dual-secreting Th17 T cells presumably are the predominant sources of the psoriasis phenotype-driving cytokines, IL-17A and IL-22.
Adamopoulos, Iannis E +12 more
core
Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort
Arthritis Care &Research, EarlyView.Objective The aim of this study was to examine patient‐reported treatment goals among individuals with psoriatic arthritis. Methods Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient‐reported outcome (PROs) instruments, between 2017 and 2020.
Astia Allenzara +8 more
wiley +1 more source
"I don't want to manage it, I want to get rid of it" : a narrative analysis of living with chronic plaque psoriasis, and an investigation into vitamin D as a treatment : a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Nutritional Science at Massey University, Albany, New Zealand [PDF]
, 2017 As a chronic skin disease, plaque psoriasis can cause significant psychosocial, emotional and physical burden. Psoriasis sufferers perceive others as lacking understanding around what it is like to live with this condition, and there has been little ...
Ingram, Michelle Anne
core
Diagnosis of Scalp Disorders using Machine Learning and Deep Learning Approach -- A Review [PDF]
arXiv, 2023 The morbidity of scalp diseases is minuscule compared to other diseases, but the impact on the patient's life is enormous. It is common for people to experience scalp problems that include Dandruff, Psoriasis, Tinea-Capitis, Alopecia and Atopic-Dermatitis. In accordance with WHO research, approximately 70% of adults have problems with their scalp.
arxiv
Arthritis Care &Research, EarlyView.As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox +3 more
wiley +1 more source